> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – June 2016

Loading EJC News Focus video

Key Advances in Clinical Trials

International Clinical Trials Day, on May 20th is an opportunity for clinical researchers and the public to celebrate progress in clinical research. It commemorates the day in 1747 when James Lind started a clinical trial on the causes of scurvy and laid the foundations for modern research.

At University College London (UK), the Institute of Clinical Trials and Methodology (ICTM) devoted the day to key advances, many in cancer research. The dramatic increase in cancer treatments poses both opportunities and challenges, Max Parmar, Director of ICTM, tells Helen Saul in this month's EJC News Focus. Statistician Melissa Spears outlines one solution in the prostate cancer trial STAMPEDE, which uses a multi-arm multi-stage (MAMS) platform. Helen Meadows describes research into rare cancers and Sara Ghorashian discusses ground-breaking research into chimeric antigen receptors (CARs).